MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$6,336K
Free Cash flow
-$16,990K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds of available for sale s...
Due to related parties
Notes receivable
Others
Negative Cash Flow Breakdown
Net (loss) income
Accounts receivable
Purchase of certificates of depo...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Gyre Pharmaceuticals
-
22,519
-
-
Gyre
-
0
-
-
All Other Segments
-
0
-
-
Revenues
-
22,519
-
-
Gyre Pharmaceuticals
-
1,227
-
-
Gyre
-
0
-
-
All Other Segments
-
0
-
-
Cost of revenues
-
1,227
-
-
Gyre Pharmaceuticals
-
14,136
-
-
Gyre
-
0
-
-
All Other Segments
-
0
-
-
Selling and marketing
-
14,136
-
-
Research and development
-
6,738
-
-
General and administrative
-
7,220
-
-
Gyre Pharmaceuticals
-
0
-
-
Gyre
-
2,553
-
-
All Other Segments
-
0
-
-
Transaction costs
-
2,553
-
-
Total operating expenses
-
31,874
-
-
(loss) income from operations
-
-9,355
-
-
Gyre Pharmaceuticals
-
0
-
-
Gyre
-
-89
-
-
All Other Segments
-
0
-
-
Change in fair value of warrant liability
-
-89
-
-
Gyre Pharmaceuticals
-
-162
-
-
Gyre
-
191
-
-
All Other Segments
-
0
-
-
Other (expense) income, net
-
29
-
-
Gyre Pharmaceuticals
-
621
-
-
Gyre
-
0
-
-
All Other Segments
-
0
-
-
Income tax expense
-
621
-
-
Net (loss) income
-22,991
-9,858
-1,366
5,936
Accrued interest on certificates of deposit
-
-
-
267
Accrued interest on bank deposit
-
-
-28
-
Change in fair value of receivables from gcbp
-
-
0
0
Change in fair value of derivative liabilities
-
-
0
0
Stock-based compensation
2,075
2,583
4,597
1,147
Equity in loss of unconsolidated affiliate
-22
-21
-20
-19
Depreciation and amortization
1,483
672
656
649
Noncash lease expense
224
217
171
206
Amortization of land use rights
-
-
39
-
Deferred income taxes, net
-1,426
-738
-87
-531
Bad debt expense and other non-cash items
-35
195
-34
-54
Accrued interest on long-term certificates of deposit
542
-647
-
-
Accretion of premium or discount on short-term investments
-10
-
-
-
Change in fair value of financial liabilities, net
220
-
-
-
Net proceeds from cvr liability settlement
-
-
0
0
Change in fair value of warrant liability
-
-89
-263
23
Foreign currency exchange gain
-39
-
-
-
Loss on disposal of property and equipment
-2
-16
-2
-1
Notes receivable
-3,472
-1,902
4,848
178
Accounts receivable
4,473
-8,573
4,825
5,981
Inventories
-94
1,015
1,208
-72
Prepaid and other assets
-2,977
912
509
-398
Income tax payable
-1,021
144
261
1,536
Accounts payable
-249
139
-433
483
Other noncurrent liabilities
-
-
-47
-
Due to related parties
4,800
-
-1
-
Accrued expenses and other liabilities
-502
683
2,380
-3,513
Operating lease liabilities
-536
-
-236
-236
Net cash used in operating activities
-16,728
3,180
-5,635
4,676
Purchase of short-term investments
-
-
-
564
Acquisition of intangible assets
1,024
5
-4
15
Purchase of certificates of deposit
2,924
12,951
2,826
0
Purchase of available for sale securities
2,032
-
-
-
Proceeds of available for sale securities
13,068
-
-
-
Purchase of property and equipment
262
178
144
668
Proceeds from sale of equipment
7
6
11
0
Proceeds from maturity of certificates of deposit
2,924
10,073
4,239
0
Net cash provided by investing activities
9,757
-3,055
1,848
-1,247
Offering costs paid
-
-
-
-315
Payments of listing expense
208
-
-
-
Proceeds from the exercise of stock options
200
-2,017
-
50
Proceeds from the issuance of common stock-May Two Thousand Twenty Five Underwritten Public Offering
-
-
-
0
Proceeds from the issuance of common stock-Two Thousand Twenty Four ATMProgram
-
-
-
0
Net cash provided by financing activities
-8
21
318
365
Effect of exchange rate changes on cash
643
285
127
117
Net (decrease) increase in cash
-6,336
431
-3,332
3,911
Cash at beginning of the period
37,501
37,070
40,402
11,813
Cash at end of period
43,287
37,501
37,070
40,402
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds of available for
sale securities
$13,068K
Proceeds from maturity of
certificates of deposit
$2,924K
(-73.87%↓ Y/Y)
Proceeds from sale of
equipment
$7K
(-63.16%↓ Y/Y)
Net cash provided by
investing activities
$9,757K
(1007.63%↑ Y/Y)
Effect of exchange rate
changes on cash
$643K
(549.49%↑ Y/Y)
Canceled cashflow
$6,242K
Net (decrease)
increase in cash
-$6,336K
(-125.67%↓ Y/Y)
Canceled cashflow
$10,400K
Due to related
parties
$4,800K
Notes receivable
-$3,472K
(10.49%↑ Y/Y)
Prepaid and other assets
-$2,977K
(-3233.68%↓ Y/Y)
Stock-based compensation
$2,075K
(46.85%↑ Y/Y)
Depreciation and
amortization
$1,483K
(26.11%↑ Y/Y)
Noncash lease expense
$224K
(-44.00%↓ Y/Y)
Inventories
-$94K
(-103.77%↓ Y/Y)
Foreign currency
exchange gain
-$39K
Equity in loss of
unconsolidated affiliate
-$22K
(42.11%↑ Y/Y)
Loss on disposal of
property and equipment
-$2K
(-100.00%↓ Y/Y)
Proceeds from the
exercise of stock options
$200K
(-89.94%↓ Y/Y)
Purchase of certificates
of deposit
$2,924K
(-73.86%↓ Y/Y)
Purchase of available for
sale securities
$2,032K
Acquisition of intangible
assets
$1,024K
(41.83%↑ Y/Y)
Purchase of property and
equipment
$262K
(-30.69%↓ Y/Y)
Net cash used in
operating activities
-$16,728K
(-953.91%↓ Y/Y)
Canceled cashflow
$15,188K
Net cash provided by
financing activities
-$8K
(-100.03%↓ Y/Y)
Canceled cashflow
$200K
Net (loss) income
-$22,991K
(-532.98%↓ Y/Y)
Accounts receivable
$4,473K
Deferred income taxes,
net
-$1,426K
(-190.43%↓ Y/Y)
Income tax payable
-$1,021K
(41.76%↑ Y/Y)
Accrued interest on
long-term certificates of...
$542K
Operating lease
liabilities
-$536K
(-97.06%↓ Y/Y)
Accrued expenses and
other liabilities
-$502K
(-124.15%↓ Y/Y)
Accounts payable
-$249K
(-572.97%↓ Y/Y)
Change in fair value of
financial liabilities,...
$220K
Payments of listing
expense
$208K
Buy us a coffee
GYRE THERAPEUTICS, INC. (GYRE)
GYRE THERAPEUTICS, INC. (GYRE)